Zimmer Biomet stock price forecast: $86.96–$89.44 range as ZBH trades up

Traders Union
All News
Financial News
Zimmer Biomet up 1.27% on earnings beat

Highlights

Zimmer Biomet delivered quarterly earnings of $2.09 per share, exceeding estimates and underscoring strong profitability momentum.
Quarterly revenue edged above forecasts at $2.09 billion, with a $0.24 per share dividend reinforcing shareholder returns.
Technicals indicate consolidation between $86.96 and $89.44, with intraday momentum favoring downside risk and only moderate short-term rebound probability.

Earnings beat and raised dividend as operational strength underpins sentiment

Zimmer Biomet reported quarterly earnings of $2.09 per share for the period ended April 28th, surpassing consensus expectations and highlighting stronger profitability for the quarter. This earnings outperformance signals continued operational momentum and supports current market demand for the stock. Additionally, revenue for the quarter reached $2.09 billion, slightly above analyst forecasts, while the company declared a quarterly dividend payout of $0.24 per share, reinforcing its commitment to shareholder returns.

Mixed outlook as shorter-term strength clashes with stalled momentum

On the technical front, ZBH trades above the MA-20 and MA-50 but remains below the MA-200, reflecting mixed time horizon signals. Immediate support is marked by the Ichimoku Kijun at $88.05, with the short-term trading range defined by support at $86.96 and resistance at $89.44. Momentum signals are mixed: RSI at 48.46 and MACD both point bearish, ADX and CCI are neutral, Stoch RSI signals a strong buy, and BBP is in oversold territory. This combination indicates that sellers dominate short-term momentum, though there are pockets of buyer activity.

Range-bound trading likely as breakout risks remain subdued

In the short term, ZBH is likely to consolidate between $86.96 and $89.44, with typical volatility expected within this range over the next two to three trading days. The probability of a move to the upside is 38%, while the chance of renewed downside stands at 62%, making a breakout less probable under current conditions. The baseline scenario calls for continued range-bound trading; an upward scenario emerges only if resistance is decisively breached, while a move below support would reinforce the short-term bearish bias.

Anton Kharitonov, expert at Traders Union, sees the recent earnings beat and modest revenue growth as short-term supportive for Zimmer Biomet, but is cautious about the stock's ability to break out. He notes that technical signals are mixed, with sellers still dominant and strong resistance at $89.44. Most indicators suggest a continued range-bound environment. "Base case remains sideways between $86.96 and $89.44 — no conviction for upside until resistance is cleared," he says.

Previously it was reported that Zimmer Biomet was experiencing sustained weakness and seller pressure in the face of its recent innovation accolades. The current earnings beat and operational momentum offer a potential shift in sentiment, with investors now advised to monitor whether the stock can decisively clear the $89.44 resistance level to affirm a change in trend.

Source of Data: ZBH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.